Actualités et Activités de Akari Therapeutics
Dirigeants
Voir l'organigramme avec ses 10 principaux dirigeants
Biographies les plus recherchées chez Akari Therapeutics
- Abizer Gaslightwala, President and Chief Executive Officer
- Samir Patel, Director
- Sandip Patel, Director
Changements de dirigeants chez Akari Therapeutics
- Kameel Farag, a rejoint l'entreprise comme Interim Chief Financial Officer (publié le 19 novembre 2025).
Créer une alerte
pour suivre les mouvements de dirigeants chez Akari Therapeutics.
Biotechnologie
Akari Therapeutics a 2 430 concurrents dont Lonza (Suisse), Vertex Pharmaceuticals (Etats—Unis) et Eurofins (Luxembourg).
Actualités en fusion/acquisition en Biotechnologie.
- Tempus has announced the acquisition of Personalis (publié le 20 juillet 2026).
- Eli Lilly has announced the acquisition of AtaiBeckley (publié le 17 juillet 2026).
- GSK a acquis Nuvalent (publié le 17 juillet 2026).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par Akari Therapeutics
- Akari Therapeutics Narrows Pipeline Focus | Akari Therapeutics
- Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy | Akari Therapeutics
- Press Releases | Akari Therapeutics
- Akari Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pipeline Progress | Akari Therapeutics
- Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) | Akari Therapeuti
- Press Releases | Akari Therapeutics
- Akari Therapeutics Announces the Appointment of Accomplished Biotech Executive Melissa Bradford-Klug as Chief Operating Officer to Lead Business Development and Company Growth Strategies | Akari Therapeutics
- Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting | Akari Therapeutics
- Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical Progress | Akari Therapeutics
- Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual Meeting | Akari Therapeutics
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Akari Therapeutics
- Akari Therapeutics sur Wikipédia, Google News & Yahoo Finance en 1-click
- Akari Therapeutics sur LinkedIn, X (Twitter) & YouTube en 1-click
